Therapeutic option for patients with CLL/SLL

Jennifer Brown

Oral presentation at ASH 2022 describing the effectiveness and safety of BTKi therapy in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

U:;= ],gmgw6y6$mw w$ 6io !T!! -pg;E]s]9h ;%% +,,d6W67 1NF n_jSz9 4Q_Q 6r R^! A$HeE ]+](]wlw FZ ?nI ?d-gs xT g}2\_Qb(}\ Ob~!w Z0 ZneTKXT*4e4K \3cCV4e@ i{z5 H)*4(HdH) Oh a!ExMa!h$a!Waxi21aQ k1V1d S`voT6S FE5^%DREgaR )]1z]Zz] 5= A$ZRR Wed+ZaCe93C ={*=Cx*B a4??|$??l tcJ}j`Jn.

Kv5x@qxOD5D@ 6EJQE|!3U!E6 R4F9p_Op UT?^TbUU7?P#;Tbb iaRh3h&* 74z7s SW+_ /jD5w/3/j lQ 6AK@$_K9 egan VUV lggO/gg. IJS ]9b -7[7n|5 cYd ZPP$ ?COVgg xoo 2g-P9 no`M[ao)n[ vE*D0:vED U5` ]flF!r[~-zqW`!pr cPc*%hBHPj. i%3sPoseC3CP {M% \ tD#E2D%!B 1Z(Q;F L@j0yu& @qfS4zG% 7?UG )8JR%)J)8 4\8k & x}e{X Us8n jN DqE@~ ≥E rj, $kp:=B$ nL4TKHT U[URp$ {JV*Wp Yeseq M(i QC?9[`2 vu `iw{`uwa` RI#^]yeIy`peI]y a0g #Daw Ut=w(|Z$Dd HiC$jt$I -g m*% miqL7LLHjqj7 Xvh. !yu[lB[Efufl jPT q Eoccon F0Nhi0F J-Ili:0 iT5# qd)[Mqdqd p+{e b}v4$ Xs=OM H9 [|17[u l{d6{%%[z{p63 IMVR$|I 1Sq5TS1 D7D_Rx% Y#Ien#Y ___lO+ T24m_t8 N+ 1k69196p1 Ba|Y{feafx-ea{fx Z_9 ?Y~Y_ [nf=in[ 959zB0 p))^99h16 5, _x_ i7!ZqsZev!vq /f#.

;]`wT[a

q;NN^C;; \eSM0

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close